FibroGen Inc (FGEN)
Official siteBIOTECHNOLOGY
Last updated: Jan 07, 2026 at 4:00 PM ET
FibroGen Inc (FGEN) Financials: Revenue, Profit and Cash Flow
FibroGen reported revenue of $29.62M for the fiscal year ended Dec 31, 2024, down 36.7% from the year before. That year, net income was -$47.58M with a net margin of -160.6%, operating cash flow was -$138.00M and free cash flow was -$138.26M. The quarter ended Sep 30, 2025 had revenue of $1.08M and net income of $200.64M.
Revenue and Margins
Over the 9 years to Dec 2024, revenue fell from $180.83M, a compound annual decline of 18.2%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2024 | $29.62M | -36.7% | 47.5% | -507.8% | -160.6% |
| Dec 2023 | $46.80M | -66.7% | 91.5% | -689.5% | -607.3% |
| Dec 2022 | $140.73M | -40.2% | 85.6% | -213.9% | -208.7% |
| Dec 2021 | $235.31M | +33.5% | 94.5% | -122.6% | -123.7% |
| Dec 2020 | $176.32M | -31.3% | 95.0% | -108.8% | -107.4% |
| Dec 2019 | $256.58M | +20.5% | 99.6% | -34.8% | -30.0% |
| Dec 2018 | $212.96M | +69.5% | -10.7% | -40.7% | -40.6% |
| Dec 2017 | $125.67M | -30.0% | -56.4% | -97.6% | -100.4% |
| Dec 2016 | $179.58M | -0.7% | -4.2% | -29.9% | -34.3% |
| Dec 2015 | $180.83M | N/A | -18.4% | -42.9% | -47.4% |
Income Statement
In the fiscal year ended Dec 2024, the net loss narrowed from the year before. In the quarter ended Sep 2025, net income turned positive after a loss in the same quarter a year earlier.
Annual
| Line item | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $29.62M | $46.80M | $140.73M | $235.31M | $176.32M | $256.58M | $212.96M | $125.67M | $179.58M | $180.83M |
| Cost of revenue | $15.56M | $3.96M | $20.28M | $12.87M | $8.87M | $1.15M | $235.84M | $196.52M | $187.21M | $214.09M |
| Gross profit | $14.06M | $42.84M | $120.45M | $222.44M | $167.45M | $255.43M | -$22.88M | -$70.85M | -$7.63M | -$33.26M |
| Research and development | $95.69M | $266.47M | $296.79M | $387.04M | $252.92M | $209.26M | $235.84M | $196.52M | $187.21M | $214.09M |
| Operating income | -$150.42M | -$322.72M | -$301.02M | -$288.53M | -$191.88M | -$89.31M | -$86.69M | -$122.61M | -$53.65M | -$77.63M |
| Net income | -$47.58M | -$284.23M | -$293.65M | -$291.03M | -$189.29M | -$76.97M | -$86.42M | -$126.20M | -$61.68M | -$85.78M |
| EBITDA | -$142.43M | -$305.20M | -$282.82M | -$273.72M | -$164.28M | -$52.31M | -$68.56M | -$104.75M | -$44.99M | -$68.83M |
Quarterly
| Line item | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.08M | $1.35M | $2.74M | -$123.26M | $46.33M | $998.00K | $25.36M | $27.14M | $40.13M | $44.32M | $36.16M | $34.37M |
| Gross profit | $1.13M | $1.26M | $2.49M | -$102.59M | $41.04M | -$31.50M | -$32.47M | $21.73M | $35.89M | $38.61M | $32.67M | $29.44M |
| Operating income | -$5.41M | -$12.05M | -$14.92M | -$91.66M | -$16.78M | -$46.41M | -$49.18M | -$54.20M | -$63.48M | -$88.05M | -$76.09M | -$66.15M |
| Net income | $200.64M | -$7.60M | $4.64M | $17.98M | -$17.08M | -$15.54M | -$32.93M | -$56.23M | -$63.62M | -$87.68M | -$76.70M | -$66.17M |
Balance Sheet
As of Dec 2024, long-term debt of $73.09M exceeded cash and equivalents by $22.61M. Shareholder equity was negative, at -$225.60M, as total liabilities of $398.16M exceeded total assets of $214.53M.
Annual
| Line item | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $214.53M | $423.53M | $610.09M | $773.82M | $826.84M | $857.40M | $880.60M | $898.65M | $469.55M | $470.57M |
| Current assets | $196.51M | $331.56M | $492.83M | $474.06M | $755.11M | $702.49M | $690.01M | $748.97M | $266.52M | $200.56M |
| Cash and equivalents | $50.48M | $113.69M | $155.70M | $171.22M | $678.39M | $126.27M | $89.26M | $673.66M | $173.78M | $153.32M |
| Total liabilities | $398.16M | $585.73M | $611.57M | $544.71M | $385.39M | $321.99M | $352.13M | $316.20M | $294.44M | $273.75M |
| Short-term debt | N/A | $14.12M | $10.29M | $10.94M | $13.52M | $12.35M | $1.09M | $57.32M | $45.03M | $43.17M |
| Long-term debt | $73.09M | $71.93M | N/A | N/A | N/A | $16.78M | $16.80M | $17.24M | $97.35M | $15.09M |
| Shareholder equity | -$225.60M | -$204.17M | -$21.45M | $209.15M | $422.18M | $516.13M | $509.20M | $563.18M | $155.84M | $177.55M |
Quarterly
| Line item | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $137.01M | $178.06M | $165.21M | $214.53M | $264.42M | $293.20M | $365.87M | $423.53M | $460.43M | $515.13M | $538.54M | $610.09M |
| Total liabilities | $119.53M | $359.08M | $340.14M | $398.16M | $466.12M | $483.58M | $552.02M | $585.73M | $575.63M | $575.43M | $567.43M | $611.57M |
| Cash and equivalents | $117.97M | $23.37M | $33.61M | $50.48M | $131.00M | $140.71M | $105.73M | $113.69M | $60.81M | $152.59M | $188.55M | $155.70M |
| Shareholder equity | -$17.03M | -$223.00M | -$216.90M | -$225.60M | -$243.67M | -$232.34M | -$228.12M | -$204.17M | -$157.17M | -$102.27M | -$48.85M | -$21.45M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2024.
Annual
| Line item | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$138.00M | -$315.02M | -$145.93M | -$82.23M | $81.60M | -$78.70M | -$76.14M | -$66.51M | $7.11M | -$18.57M |
| Capital expenditures | $266.00K | $2.52M | $38.74M | $30.19M | $3.99M | $5.76M | $8.02M | $8.50M | $1.25M | $1.98M |
| Free cash flow | -$138.26M | -$317.54M | -$184.67M | -$112.42M | $77.61M | -$84.47M | -$84.16M | -$75.01M | $5.86M | -$20.55M |
| Dividends paid | $2.23M | $2.25M | $5.17M | $7.37M | $11.46M | $12.75M | N/A | $0 | $0 | $0 |
| Investing cash flow | $125.99M | $153.66M | $89.12M | -$426.97M | $452.49M | $120.02M | -$522.12M | $69.87M | $6.62M | -$5.87M |
| Financing cash flow | -$255.00K | $122.75M | $46.78M | -$563.00K | $13.34M | -$4.30M | $13.88M | $496.47M | $6.74M | $12.35M |
Quarterly
| Line item | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.85M | $12.68M | $2.72M | -$30.47M | -$8.38M | -$39.87M | -$59.29M | -$18.32M | -$84.54M | -$110.57M | -$101.59M | -$52.51M |
| Capital expenditures | $9.00K | $13.00K | $16.00K | $141.00K | $82.00K | $14.00K | $29.00K | $251.00K | $684.00K | $993.00K | $591.00K | $333.00K |
| Free cash flow | -$1.86M | $12.67M | $2.70M | -$30.61M | -$8.46M | -$39.88M | -$59.32M | -$18.57M | -$85.22M | -$111.56M | -$102.18M | -$52.85M |
Frequently Asked Questions About FGEN
What is FibroGen's annual revenue?
FibroGen reported revenue of $29.62M for the fiscal year ended Dec 31, 2024.
How fast is FibroGen's revenue growing?
Revenue was down 36.7% for the fiscal year ended Dec 31, 2024 compared with the year before. The compound annual revenue growth rate over 3 years was -49.9%.
Is FibroGen profitable?
No. FibroGen reported net income of -$47.58M for the fiscal year ended Dec 31, 2024, with a net margin of -160.6%.
How much free cash flow does FGEN generate?
For the fiscal year ended Dec 31, 2024, operating cash flow of -$138.00M minus capital expenditures of $266.00K produced free cash flow of -$138.26M.
How much debt does FibroGen have?
The balance sheet dated Dec 31, 2024 reported long-term debt of $73.09M and cash and equivalents of $50.48M.
FGEN pages: Overview, Financials